Tobevibart (VIR-3434)

Monoclonal antibody

Also known as BRII-877

Phase 3topline reported

Evidence outlook · registrational

Chronic Hepatitis Delta: topline reported 2026-11-08

Its supporting mid-stage studies have completed. The sponsor reported topline results on 2026-11-08 (ECLIPSE 1 Phase 3 meets its primary endpoint). The announcement is listed under Regulatory events.

Latest reported trial: SOLSTICE (NCT05461170) · Phase 2 · met primary endpoint · grade pending

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Chronic Hepatitis Delta
Phase 2 (4)
Chronic Hepatitis Delta
NCT07142811 · Vir Biotechnology, Inc.
2025-08-05 – 2030-07 · Viral Hepatitis
What this study did
Other / comorbidity
NCT06216470 · University Health Network, Toronto
2024-03-13 – 2029-12 · Hepatitis B, Chronic
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT05612581 · Vir Biotechnology, Inc.
2023-05-10 – 2025-08-19 · Hepatitis B, Chronic
What this study did
Phase 1 (3)
Other / comorbidity
NCT06070051 · Virion Therapeutics
2023-09-26 – 2026-03-31 · Chronic Hepatitis B
What this study did
NCT05484206 · Vir Biotechnology, Inc.
2022-09-21 – 2025-12-09 · Hepatic Impairment, Cirrhosis
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Chronic Hepatitis Delta: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tobevibart (VIR-3434): this drugPhase 3Monoclonal antibodyHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)
Approved(overall)
Protein / enzyme therapeuticHBsAg
not yet graded(overall)
No reviewed efficacy summary in this indication
HepalatidePhase 3PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (I.V.-Hepabig)
Phase 3(overall)
Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAg
not yet graded(overall)
No reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 3Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
ACT201
Phase 1(overall)
RNA / oligonucleotideHBsAg
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tobevibart (VIR-3434) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Chronic Hepatitis DeltaActive not recruiting
Est. primary completion 2026-12 · NCT07128550 · CT.gov ↗
What to watch
2029 (2)
March 2029 (1)
Phase 2Chronic Hepatitis DeltaActive not recruiting
Est. primary completion 2029-03 · NCT07142811 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Hepatitis B, ChronicRecruiting
Est. primary completion 2029-12 · NCT06216470 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 2Hepatitis D, ChronicActive not recruiting
Est. primary completion 2031-11 · NCT05461170 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 November 2026Topline resultECLIPSE 1 Phase 3 meets its primary endpoint
Vir Biotechnology · Source ↗